Analysts forecast that Autolus Therapeutics plc (NASDAQ:AUTL – Get Rating) will announce earnings per share of ($0.49) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Autolus Therapeutics’ earnings. The highest EPS estimate is ($0.44) and the lowest is ($0.57). Autolus Therapeutics posted earnings of ($0.47) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 4.3%. The firm is expected to report its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Autolus Therapeutics will report full year earnings of ($1.98) per share for the current fiscal year, with EPS estimates ranging from ($2.28) to ($1.73). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.98) per share, with EPS estimates ranging from ($2.38) to ($1.60). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Autolus Therapeutics.
Autolus Therapeutics (NASDAQ:AUTL – Get Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.10. Autolus Therapeutics had a negative net margin of 6,098.54% and a negative return on equity of 49.80%. During the same period in the previous year, the firm earned ($0.53) EPS.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. MYDA Advisors LLC grew its position in Autolus Therapeutics by 102.3% during the 3rd quarter. MYDA Advisors LLC now owns 171,953 shares of the company’s stock worth $1,126,000 after purchasing an additional 86,953 shares during the period. Jump Financial LLC lifted its holdings in Autolus Therapeutics by 39.5% in the third quarter. Jump Financial LLC now owns 65,900 shares of the company’s stock valued at $432,000 after acquiring an additional 18,645 shares during the period. Cetera Investment Advisers purchased a new stake in Autolus Therapeutics in the 3rd quarter worth approximately $688,000. Frazier Management LLC grew its stake in shares of Autolus Therapeutics by 6.1% during the 4th quarter. Frazier Management LLC now owns 3,746,857 shares of the company’s stock worth $19,446,000 after purchasing an additional 216,200 shares during the period. Finally, Wealth Effects LLC purchased a new position in shares of Autolus Therapeutics during the 4th quarter valued at approximately $119,000. Institutional investors own 61.45% of the company’s stock.
Autolus Therapeutics stock opened at $2.84 on Thursday. Autolus Therapeutics has a one year low of $2.83 and a one year high of $8.23. The business’s fifty day moving average is $3.89 and its 200 day moving average is $4.77. The stock has a market capitalization of $258.18 million, a PE ratio of -1.53 and a beta of 1.60.
About Autolus Therapeutics (Get Rating)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.
- Get a free copy of the StockNews.com research report on Autolus Therapeutics (AUTL)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.